Clinical trials
Metastatic Prostate Cancer clinical trials
Below are recruiting metastatic prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04086290RecruitingPhase 1/Phase 2
Surgery plus targeted radiation for prostate cancer spread
This study looks at whether combining prostate surgery with a highly focused radiation treatment (SBRT) can control prostate cancer that has spread to a limited number of bones. It may help patients by treating the main tumor and the specific metastatic spots in a controlled way.
HerlevAges 18 years+ - NCT03294889RecruitingPhase 1/Phase 2
Single-dose SBRT for early prostate cancer
This trial tests a very short, one-time form of radiation (SBRT) to treat prostate cancer. It aims to see whether treating the prostate in one shot is safe and effective for carefully selected patients.
GenevaAges 18–85 - NCT03541928RecruitingPhase 2
Gene therapy with standard treatment for high-risk prostate cancer
This trial combines gene therapy with hormone therapy, radiation, and possibly surgery to treat high-risk prostate cancer. It aims to improve outcomes by adding gene therapy to standard treatments and will require additional biopsies.
Houston, TexasAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT05597852Recruiting
Rectal gel spacer to help repeat prostate radiation
This trial studies whether placing a soft gel spacer near the rectum can make “salvage” prostate radiation safer and more tolerable when prostate cancer comes back locally. It may help reduce side effects by creating extra space between the rectum and the radiation area.
Toronto, OntarioAges 18 years+ - NCT05241236Recruiting
Laser ablation guided by MRI and ultrasound for prostate cancer
This trial looks at a treatment that uses MRI and ultrasound to guide a laser to destroy prostate cancer. It may help men with low- or intermediate-risk prostate cancer who do not have spread beyond the prostate.
Miami Lakes, FloridaAges 50 years+ - NCT05753566RecruitingPhase 2
Rezvilutamide for prostate cancer PSA rise after prostate surgery
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Nanjing, JiangsuAges 40 years+ - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT04861415Recruiting
Testing a shorter radiation plan versus standard prostate radiation
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
Toronto, OntarioAges 18 years+ - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT05983783RecruitingPhase 3
Testing two drug combinations for advanced prostate cancer
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
Nanjing, JiangsuAges 40–80 - NCT05832736Recruiting
Robot surgery for one-sided prostate cancer with urethra preserved
This study looks at a robotic prostate operation that aims to remove only the affected side while keeping the urethra (the tube for urination) to help preserve urinary function. It’s for people with low- to intermediate-risk, one-sided prostate cancer and no spread to lymph nodes, bones, or other organs.
Candiolo, TOAges 40 years+ - NCT07871110RecruitingPhase 2
New pill combined with hormone therapy for advanced prostate cancer
This study tests a new pill (TT00420) taken with standard hormone therapy for prostate cancer that has spread and is no longer responding to initial hormone treatment. The goal is to see if the combination can help slow the cancer's growth and is safe.
Fuzhou, FujianAges 18 years+ - NCT07871435RecruitingPhase 1/Phase 2
Investigational combo for advanced prostate cancer
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT06249750RecruitingPhase 2
Heat shock therapy for castration-resistant prostate cancer
This trial tests a near-infrared whole-body heat shock technique to treat prostate cancer that no longer responds to hormone therapy. It aims to see if this heat-based approach can help control the cancer.
Hangzhou, ZhejiangAges 18–90 - NCT07869836RecruitingPhase 3
Comparing new drug to standard chemo for advanced bladder cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
Macon, GeorgiaAges 18 years+ - NCT07863986Recruiting
Studying response to lutetium therapy for advanced prostate cancer
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
KaunasAges 18 years+ - NCT04612907Recruiting
Radiation timing options for low-burden metastatic prostate cancer
This study compares different radiation schedules to the main prostate tumor in men with low-burden metastatic (spread) hormone-sensitive prostate cancer. It may help find a radiation timing approach that controls the cancer while balancing side effects.
UmeåAges 18 years+ - NCT06321679Recruiting
Study of bone scans for advanced prostate cancer treatment
This trial is testing how well treatments for advanced prostate cancer that has spread to the bones can be seen on scans. It may help doctors find better ways to measure if the cancer is responding to treatment.
MilanAges 18 years+ - NCT04838899Recruiting
Radiation for limited, progressing prostate cancer on abiraterone
This study tests whether a very focused type of radiation (SABR) can control a small number of prostate cancer spots that are starting to grow while you’re already on abiraterone. It may help by treating only the areas that are progressing, while other areas remain controlled.
Toronto, OntarioAges 18 years+ - NCT06260410Recruiting
Lu-PSMA prostate cancer data study
This study collects information (like scans and blood tests) from men with prostate cancer who are about to start Lu-PSMA therapy. The goal is to track how the cancer responds and learn more about its features during treatment.
Rotterdam, South HollandAges 18 years+ - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT07853209RecruitingPhase 3
A study of a radioactive drug for men with metastatic prostate cancer
This study tests a new radioactive drug (called [177Lu]Ludotadipep) that targets a molecule on prostate cancer cells. It may help slow cancer growth in men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy.
Gyeonggi-doAges 19 years+
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Metastatic Prostate Cancer trials by city
Studies with a site in or near these metro areas.
Metastatic Prostate Cancer trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for metastatic prostate cancer?
- Yes. Clin2 currently lists 717 recruiting metastatic prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer Metastatic Disease
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.